ABOS vs BLK · $73.3M cap vs P/E 27, rev $24.22B
Acumen Pharmaceuticals Inc (ABOS) versus BlackRock Inc (BLK) — a side-by-side from cached financials, not a winner call.
Acumen Pharmaceuticals Inc (ABOS) is a biotechnology company listed on US.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
ABOS does not have a complete income-statement cache yet.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
ABOS currently screens at market cap $73.3M. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Not investment advice. Open the ABOS and BLK stock pages for the full models.
Not investment advice.